Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial ...

San Francisco, USA-based Chai Discovery, the AI company building a computer-aided design suite for molecules, has announced a ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

Shortly after securing a partnership with Sanofi, InduPro is linking up with Eli Lilly in efforts to discover new cancer ...

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Eli Lilly and Company (Lilly) to accelerate biologics discovery using ...

Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma industry by market cap. | Two investigational cardiometabolic drugs from Eli ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...

InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the ...

AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional ...